Evidence map›Paper›PMID 33126605›Full record

ArticleInternational journal of molecular sciences2020

Associations of

Jer-Hwa Chang, Tsung-Ching Lai, Po-Jen Yang, Pei-Chun Shih, Yi-Chieh Yang, Kai-Ling Lee, Tu-Chen Liu, Thomas Chang-Yao Tsao, Shun-Fa Yang, Ming-Hsien Chien

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genetic Associations ofInternational journal of environmental research and public health · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Jer-Hwa ChangSchool of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-1306-2089
Tsung-Ching LaiDivision of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.
Po-Jen YangSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Pei-Chun ShihDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei 100225, Taiwan.
Yi-Chieh YangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Kai-Ling LeeGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Tu-Chen LiuDepartment of Chest Medicine, Cheng-Ching General Hospital, Taichung 407, Taiwan.
Thomas Chang-Yao TsaoSchool of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0002-0365-7927
Ming-Hsien ChienPulmonary Research Center, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.
Chung Shan Medical University Hospital · TWTaipei Medical University Hospital · TWWan Fang Hospital · TWCheng Ching Hospital · TWNational Taiwan University Hospital · TWTungs' Taichung MetroHarbor Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LADC) is a major subtype of lung cancer, particularly among populations of East Asia. The epidermal growth factor receptor (EGFR) is the most frequently mutated oncogene promoting LADC progression and can serve as a therapeutic target in LADC. The tissue inhibitor of metalloproteinases (TIMP)-3 is a major regulator of extracellular matrix turnover via targeting of matrix metalloproteinases (MMPs), and thus, plays a critical role in tumor development and progression. The purpose of this study was to investigate potential associations among TIMP-3 genetic polymorphisms, EGFR statuses, and cancer clinicopathologic development in patients with LADC. In this study, 277 LADC patients with different EGFR statuses were recruited to dissect the allelic discrimination of TIMP-3 -1296 T>C (rs9619311), TIMP3 249T>C (rs9862), and TIMP3 261C>T (rs11547635) polymorphisms using a TaqMan allelic discrimination assay. Our data showed that compared to those LADC patients with wild-type CC homozygotes of TIMP-3 rs9862, patients harboring TT homozygotes of rs9862 were at a higher risk of developing mutant EGFR (adjusted odds ratio (AOR) = 2.530; 95% confidence interval (CI): 1.230-5.205;

Indexed as

Gene Expression Regulation, NeoplasticMutationAdenocarcinoma of LungAgedBiomarkers, TumorCase-Control StudiesErbB ReceptorsFemaleFollow-Up StudiesHumansLung NeoplasmsMalePrognosisSurvival RateTissue Inhibitor of Metalloproteinase-3Biomarkers, TumorEGFR protein, humanErbB ReceptorsTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3epidermal growth factor receptorlung adenocarcinomamutationpolymorphismtissue inhibitor of metalloproteinases-3

Identifiers

PMID33126605
PMCPMC7662501
OpenAlexW3094649002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.